UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
Stocks · News reference
Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
https://x.com/SemiAnalysis_/status/2111162214891610496
Tech stocks declined on October 16, 2026, as investors rotated into defensive sectors. The Nasdaq Composite fell 1.09% while the S&P 500 dropped 0.34%, with energy, materials, and financial stocks leading gains. Chipmakers faced selling pressure amid concerns about borrowing costs and AI debt fears. Tesla erased early gains, Netflix declined following leadership changes, and CoreWeave tumbled nearly 10%.
Fermi Inc. (FRMI) eases near-term debt with a key MUFG loan amendment while preparing for Q3 earnings. Get the full market update.
The Federal Reserve's 0.25% rate hike in September, with inflation at 3.7%, signals potential additional hikes in 2026. Rising interest rates affect retail stocks differently: Costco and Walmart are positioned to benefit from higher inflation and affluent consumers trading down, while Home Depot faces headwinds from reduced home improvement spending due to higher mortgage rates. Target's turnaround momentum could be threatened by inflation-weary consumers seeking bargains.